Eton Pharmaceuticals (NASDAQ:ETON) Insider Sells $235,935.00 in Stock

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) insider Ipek Erdogan-Trinkaus sold 3,500 shares of the firm’s stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $67.41, for a total transaction of $235,935.00. Following the completion of the transaction, the insider directly owned 4,081 shares of the company’s stock, valued at approximately $275,100.21. This trade represents a 46.17% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Eton Pharmaceuticals Stock Down 10.2%

NASDAQ:ETON traded down $6.95 on Thursday, hitting $61.45. 1,015,747 shares of the company’s stock were exchanged, compared to its average volume of 462,978. The firm has a 50-day moving average price of $55.19 and a 200-day moving average price of $37.24. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.79 and a quick ratio of 1.58. Eton Pharmaceuticals, Inc. has a 52 week low of $14.27 and a 52 week high of $70.64. The company has a market cap of $1.77 billion, a P/E ratio of 40.70 and a beta of 0.89.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its quarterly earnings data on Thursday, November 5th. The company reported $0.50 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.19. The company had revenue of $57.93 million during the quarter, compared to the consensus estimate of $41.98 million. Eton Pharmaceuticals had a net margin of 35.35% and a return on equity of 104.82%. As a group, analysts expect that Eton Pharmaceuticals, Inc. will post 1.13 EPS for the current fiscal year.

Institutional Trading of Eton Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the business. Hilton Head Capital Partners LLC bought a new position in shares of Eton Pharmaceuticals during the 3rd quarter worth approximately $26,000. Global Retirement Partners LLC bought a new stake in Eton Pharmaceuticals in the 3rd quarter valued at $26,000. Morse Asset Management Inc bought a new stake in Eton Pharmaceuticals in the 3rd quarter valued at $35,000. Sterling Capital Management LLC raised its stake in Eton Pharmaceuticals by 845.7% in the 3rd quarter. Sterling Capital Management LLC now owns 889 shares of the company’s stock valued at $46,000 after acquiring an additional 795 shares during the period. Finally, Toth Financial Advisory Corp acquired a new stake in Eton Pharmaceuticals during the 2nd quarter valued at $43,000. 27.86% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. B. Riley Financial increased their price target on Eton Pharmaceuticals from $70.00 to $81.00 and gave the company a “buy” rating in a research report on Tuesday. HC Wainwright boosted their price target on Eton Pharmaceuticals from $70.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday, November 6th. Craig Hallum reiterated a “buy” rating and set a $78.00 price objective on shares of Eton Pharmaceuticals in a research note on Thursday, October 15th. Canaccord Genuity Group increased their price objective on Eton Pharmaceuticals from $68.00 to $80.00 and gave the company a “buy” rating in a report on Friday, November 6th. Finally, Weiss Ratings raised shares of Eton Pharmaceuticals from a “hold (c)” rating to a “buy (b-)” rating in a research note on Monday. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $79.75.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited treatment options. Its work includes bringing new medicines and reformulated or otherwise specialized drug products to market. The company’s products include Alkindi Sprinkle, a hydrocortisone granule formulation used to treat adrenal insufficiency, and Eprontia, an oral solution of topiramate used to treat certain seizure disorders and prevent migraines.